Plain-English translation of NCT07069556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a follow-up study testing ColoSense, a stool-based test designed to screen for colorectal cancer. Researchers want to confirm that the test accurately detects cancer and pre-cancerous conditions in a large group of people. The study will enroll about 12,500 participants and measure how well the test works compared to colonoscopy, the standard screening procedure.
Colorectal cancer is a serious health concern, but it's often preventable when caught early. This medication aims to offer a simpler, less invasive screening option than colonoscopy, which may help more people get screened regularly.
You likely qualify if…
You likely don't qualify if…
You will provide a stool sample at home and return it to the study team. Within 120 days, you will undergo a routine colonoscopy as scheduled. The researchers will compare your stool test results to your colonoscopy results to see how accurately the test detected cancer and precancerous conditions. The study does not involve any medications or special procedures beyond what you would normally have for screening.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Sponsor
Geneoscopy, Inc.
Enrollment target
~12,500 participants
Started
September 2025
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Erica K Barnell, MD PhD
Geneoscopy, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.